Crafting In Vivo Glycobiology Disease Models Through Gene Expression and Glycobiology Expertise

The development of disease models frequently relies on the regulation or alterations in the expression of particular genes. Some diseases are linked to irregularities in the expression of specific genes, whereas others result from mutations in the expression of specific genes. CD BioGlyco has conducted extensive research in Glycobiology Disease Model Development for many years. We offer advanced knowledge and expertise in creating in vivo glycobiology disease models using a range of Technologies, such as gene editing, transgenic methods, embryo implantation and cultivation, selective breeding, and gene expression.

• Firstly, our experts identify the genes associated with the disease based on the glycobiological disease under study through literature research and gene expression profiling.
• We consider the similarity of simulating human diseases and the convenience of experimental manipulation, it is vital to choose the right animal model to choose the right animal model, such as mice, rats, zebrafish, and so on. The target gene is then altered or overexpressed in the animal model using gene editing technology or transgenic animal technology. This is achieved by gene knockout, knock-in, point mutation, or genome editing.
• Our experts then conduct a detailed evaluation of the phenotypic characteristics of the edited or transgenic animals, including physiological, behavioral, biochemical, and histological characteristics. This helps determine whether animal models associated with target glycobiological diseases have been successfully constructed. Moreover, we induce or simulate the occurrence and progression of target glycobiological diseases through the manipulation of animal models or the introduction of specific conditions.
• Finally, our experts conduct monitoring and assessment of glycobiological disease models, including tracking disease progression, changes in physiological parameters, and potential associated symptoms. Simultaneously, statistical and bioinformatics analysis is utilized to gain an understanding of the characteristics and mechanisms of the disease model. Based on initial evaluation findings, the model is refined and validated.

Publication

Applications

• By utilizing gene expression-based disease model development technology, various in vivo disease models related to gene expression and glycobiology can be constructed for the study of disease pathogenesis, progression, and possible targets.
• The efficacy and safety of potential drug candidates can be assessed through the use of gene expression-based disease models. This can be used to help accelerate the drug development process and provides a reliable platform for drug screening and optimization.
• Researchers are utilizing this technology as a platform to investigate the mechanisms of gene expression regulation associated with glycobiology, contributing to a more comprehensive understanding of the interactions between glycosylation and gene expression in biological systems.

Advantages

• Our experts use live animals as models to better simulate the process of disease onset and progression in living organisms with a higher degree of biological realism.
• Our technology is suitable for a variety of different types of diseases, including diseases of high complexity, such as cancer, neurological diseases, and metabolic diseases.
• The in vivo model technology at CD BioGlyco offers better experimental control and enables a more accurate study of disease biology.

CD BioGlyco offers a comprehensive gene expression-based in vivo glycobiology disease model development service to our clients. Our team has significant expertise in this area and is committed to delivering dependable, top-notch models for research needs. If you need further details, please feel free to contact us.